Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Emerg Infect Dis ; 27(12): 3133-3136, 2021 12.
Article in English | MEDLINE | ID: covidwho-1496965

ABSTRACT

As the coronavirus pandemic continues, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) sequence data are required to inform vaccine efforts. We provide SARS-CoV-2 sequence data from South Sudan and document the dominance of SARS-CoV-2 lineage B.1.525 (Eta variant) during the country's second wave of infection.


Subject(s)
COVID-19 , SARS-CoV-2 , Humans , Pandemics , South Sudan/epidemiology
2.
Nat Microbiol ; 6(8): 1094-1101, 2021 08.
Article in English | MEDLINE | ID: covidwho-1294473

ABSTRACT

Here, we report SARS-CoV-2 genomic surveillance from March 2020 until January 2021 in Uganda, a landlocked East African country with a population of approximately 40 million people. We report 322 full SARS-CoV-2 genomes from 39,424 reported SARS-CoV-2 infections, thus representing 0.8% of the reported cases. Phylogenetic analyses of these sequences revealed the emergence of lineage A.23.1 from lineage A.23. Lineage A.23.1 represented 88% of the genomes observed in December 2020, then 100% of the genomes observed in January 2021. The A.23.1 lineage was also reported in 26 other countries. Although the precise changes in A.23.1 differ from those reported in the first three SARS-CoV-2 variants of concern (VOCs), the A.23.1 spike-protein-coding region has changes similar to VOCs including a change at position 613, a change in the furin cleavage site that extends the basic amino acid motif and multiple changes in the immunogenic N-terminal domain. In addition, the A.23.1 lineage has changes in non-spike proteins including nsp6, ORF8 and ORF9 that are also altered in other VOCs. The clinical impact of the A.23.1 variant is not yet clear and it has not been designated as a VOC. However, our findings of emergence and spread of this variant indicate that careful monitoring of this variant, together with assessment of the consequences of the spike protein changes for COVID-19 vaccine performance, are advisable.


Subject(s)
COVID-19/epidemiology , SARS-CoV-2/genetics , Spike Glycoprotein, Coronavirus/genetics , Amino Acid Motifs , Coronavirus Nucleocapsid Proteins/genetics , Genetic Variation/genetics , Genome, Viral/genetics , Humans , Phosphoproteins/genetics , Phylogeny , Uganda/epidemiology , Viral Proteins/genetics
3.
Emerg Infect Dis ; 26(10): 2411-2415, 2020 10.
Article in English | MEDLINE | ID: covidwho-625963

ABSTRACT

We established rapid local viral sequencing to document the genomic diversity of severe acute respiratory syndrome coronavirus 2 entering Uganda. Virus lineages closely followed the travel origins of infected persons. Our sequence data provide an important baseline for tracking any further transmission of the virus throughout the country and region.


Subject(s)
Betacoronavirus/genetics , Coronavirus Infections/epidemiology , Coronavirus Infections/virology , Pandemics/prevention & control , Pneumonia, Viral/epidemiology , Pneumonia, Viral/virology , Air Travel , COVID-19 , Coronavirus Infections/diagnosis , Coronavirus Infections/prevention & control , Genetic Variation , Genome , Health Policy , Humans , Mass Screening , Motor Vehicles , Phylogeography , Pneumonia, Viral/diagnosis , Pneumonia, Viral/prevention & control , Quarantine , SARS-CoV-2 , Uganda/epidemiology
SELECTION OF CITATIONS
SEARCH DETAIL